As an early funder of Edgewise Therapeutics we are pleased to share that Edgewise has reported positive two-year topline results from their ARCH open label trial in hashtag#Becker Muscular Dystrophy.
#FuturesForAll #CureDuchenne #Duchenne #DMD
cureduchenne.org/all-news/edgew…

It's not too late to join us for a for a complimentary dinner session in Pittsburgh tomorrow!
Register here: bit.ly/3xD9CdK

Miami community comes together for CureDuchenne, raising nearly $2.5M since 2021.

Read at rarerevolutionmagazine.com/miami-communit…

#PressRelease #Duchenne

Our team is heading to Long Island this weekend for the CureDuchenne Family Workshop. We look forward to discussing ways to pave a positive path forward for the #Duchenne community. #raredisease

“We are seeing adults whose coverage is minimal to none and we’re able to get them back to the system. That’s one of our biggest achievements: helping people that were off the grid for so long because they couldn’t find anybody.' - Dr. Diana Castro
cureduchenne.org/general/revolu…

Join us for a session with ITF Therapeutics. Meet members of the ITF Therapeutics team to learn more about their organization and next steps to support the availability of DUVYZAT.
Please register in advance: bit.ly/43Cx1YF

CureDuchenne Community Webinar | Update with ITF Therapeutics: Introducing DUVYZAT™ (givinostat)
#FDA #Duchenne #CureDuchenne #DMD
cureduchenne.org/event/webinar-…

Check out these scholarships, aimed at those with Duchenne and/or disabilities!
cureduchenne.org/general/these-…

FDA Approves Duvyzat (givinostat) for Duchenne Treatment. Read the full press release here:
#DMD #duchenne #duchenne musculardystrophy #FDA cureduchenne.org/all-news/fda-a…

PTC Therapeutics announced that, based on recent feedback from the FDA, by mid-year they plan to re-submit an NDA for Translarna (ataluren) for Duchenne caused by nonsense mutations: press release cureduchenne.org/research/ptc-t…

Join us for an exclusive adventure at @discoverycove, offered only to attendees of the FUTURES annual conference hosted by CureDuchenne! 🐬

Learn more: web.cvent.com/event/8ff259d6…

Your power wheelchair or scooter helps you go between classes, keep up with your friends, and even stand. To make it most effective and truly make it yours, you’ll want to add extra accessories and add-ons. Browse the list!
cureduchenne.org/general/16-bes…

In case you missed it! ✈️🚌🚂
Check out today's recording of Ask Me Anything: Traveling with Duchenne with Marissa Penrod, Adam Malone and Alan Chaulet.
All Wheels Up ♿✈

cureduchenne.org/webinars/ask-m…

Our very own Chief Scientific Officer, Dr. Michael Kelly, shares his expert perspective with @Biospace on the evolving landscape of Duchenne treatments and what data and decisions we can anticipate this year. Dive into the full article here: biospace.com/article/itf-ge…

March 9: CureDuchenne to Host “Champions in Miami” Event bit.ly/3TrErKP #DMD #DuchenneMuscularDystrophy #MuscularDystrophy CureDuchenne

#RegenXBio shared interim data from their Phase 1/2 gene therapy clinical trial for individuals with Duchenne aged 4-11 years old. #Duchenne #DMD

cureduchenne.org/all-news/regen…

They want to save the lives of their boys and others who suffer from Duchenne muscular dystrophy. Many with the disease lose their lives in their late 20s. And, that's why the Finazzo family works so hard to alter fate. cbsnews.com/miami/news/sou…

Today is #RareDiseaseDay . It brings much-needed awareness to the 300 million of us around the world living with a rare disease. These are the over 6,000 diseases affecting fewer than 200,000 people in the US. 25-30 million Americans are affected by one

Sarepta Therapeutics' Route 79 Scholarship Program supports individuals within the Duchenne community who are setting out to achieve their educational dreams. sarepta.com/about-us/grant…

A heartfelt thank you to the Foster family for courageously sharing their journey with CBS 17. Your experiences and strength are incredibly inspiring to families touched by Duchenne muscular dystrophy.
cbs17.com/news/local-new…